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Research
Most epidemiological studies have shown an 
elevated risk for cardiovascular events associ-
ated with exposure to fine particulate mat-
ter (PM) (de Hartog 2003; de Hartog et al. 
2009; Peters et al. 2001, 2004; Schwartz 
1997). PM has been associated with increased 
risks of myocardial infarction (MI), stroke, 
arrhythmia, and heart failure within hours to 
days of exposure in susceptible individuals. 
In addition, air pollutants have been linked 
with intermediate outcomes that may reflect 
mecha  nistic links, including endothelial 
dysfunction and vasoconstriction, increased 
blood pressure (BP), prothrombotic and coag-
ulant changes, systemic inflammatory and 
oxidative stress responses, autonomic imbal-
ance and arrhythmias, and the progression of 
atherosclerosis (Brook et al. 2010).
Lipoprotein-associated phospholipase 
A2 (Lp-PLA2), a member of the phospholi-
pase superfamily, is an enzyme produced by 
monocytes and macrophages, T cells, and 
mast cells. Oxidized low-density lipoprotein 
(LDL) within the subendothelial space is con-
verted by Lp-PLA2 into oxidized free fatty 
acids and lysophoshatidylcholine (Macphee 
et al. 1999; Zalewski and Macphee 2005). 
These products trigger an inflammatory cas-
cade by stimulating the expression of adhe-
sion molecules and the release of cytokines 
by endothelial cells and plaque-based macro-
phages, which recruit more monocytes into 
the subendothelial space where they become 
activated and differentiate into macrophages. 
The fact that Lp-PLA2 is produced locally 
within atherosclerotic lesions itself likely 
accounts for its high specificity for vascular as 
opposed to systematic inflammation (Lerman 
and McConnell 2008). Plasma Lp-PLA2 lev-
els are not affected by systemic inflammatory 
diseases such as rheumatoid arthritis, osteo-
arthritis, or chronic obstructive pulmonary 
disease (Lerman and McConnell 2008).
Plasma Lp-PLA2 is bound mainly to LDL. 
Epidemiological studies have found consistent 
and statistically significant positive associations 
between Lp-PLA2 mass or activity and coro-
nary artery disease and stroke (Anderson 2008; 
Gorelick 2008; Koenig and Khuseyinova 
2009; Koenig et al. 2009). Lp-PLA2 is a 
marker of cardiovascular risk independent 
of and in addition to traditional risk factors 
[Lp-PLA(2) Studies Collaboration et al. 2010], 
and Lp-PLA2 may be directly involved in the 
causal pathway of plaque inflammation and the 
formation of rupture-prone plaques (Lerman 
and McConnell 2008).
This study was performed to investigate 
whether exposure to ambient particulate and 
gaseous air pollutants is associated with a sys-
temic increase in Lp-PLA2 levels, consistent 
with our hypothesis that Lp-PLA2 may be a 
potential mediator in the pathway between 
air pollution and cardiovascular disease.
Materials and Methods
Study design and study population. A prospec-
tive longitudinal study of post-MI patients 
was conducted in Augsburg, Germany, and 
two adjacent counties (a total of 300,000 
inhabits were living in the three counties at 
the time of the study) as part of a study on 
Air Pollution and Inflammatory Response 
in Myocardial Infarction Survivors: Gene-
Environment Interaction in a High Risk 
Group (AIRGENE) (Peters et al. 2007). Up to 
six repeated clinical examinations were sched-
uled every 4–6 weeks between May 2003 and 
March 2004 in six European cities (Athens, 
Greece; Augsburg, Germany; Barcelona, 
Spain; Helsinki, Finland; Rome, Italy; and 
Stockholm, Sweden). In total, 1,142 clinical 
examinations were performed. Supplementary 
to the multicenter AIRGENE protocol, we 
assessed repeated Lp-PLA2 plasma levels only 
in participants from the Augsburg region.
Candidates for the study were identi-
fied from the Augsburg MI registry. MI was 
defined according to recommendations by the 
European Society of Cardiology/American 
College of Cardiology Committee (Alpert 
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Ba c k g r o u n d: Increasing evidence suggests a proatherogenic role for lipoprotein-  associated 
  phospholipase A2 (Lp-PLA2). A meta-analysis of published cohorts has shown that Lp-PLA2 is an 
independent predictor of coronary heart disease events and stroke.
oB j e c t i v e: In this study, we investigated whether the association between air pollution and cardio-
vascular disease might be partly explained by increased Lp-PLA2 mass in response to exposure.
Me t h o d s: A prospective longitudinal study of 200 patients who had had a myocardial infarction 
was performed in Augsburg, Germany. Up to six repeated clinical examinations were scheduled 
every 4–6 weeks between May 2003 and March 2004. Supplementary to the multicenter AIRGENE 
protocol, we assessed repeated plasma Lp-PLA2 concentrations. Air pollution data from a fixed 
monitoring site representing urban background concentrations were collected. We measured hourly 
means of particle mass [particulate matter (PM) < 10 µm (PM10) and PM < 2.5 µm (PM2.5) in aero-
dynamic diameter] and particle number concentrations (PNCs), as well as the gaseous air pollutants 
carbon monoxide (CO), sulfur dioxide (SO2), ozone (O3), nitric oxide (NO), and nitrogen dioxide 
(NO2). Data were analyzed using mixed models with random patient effects.
re s u l t s: Lp-PLA2 showed a positive association with PM10, PM2.5, and PNCs, as well as with CO, 
NO2, NO, and SO2 4–5 days before blood withdrawal (lag 4–5). A positive association with O3 was 
much more immediate (lag 0). However, inverse associations with some pollutants were evident at 
shorter time lags.
co n c l u s i o n: These preliminary findings should be replicated in other study populations because 
they suggest that the accumulation of acute and subacute effects or the chronic exposure to ambient 
particulate and gaseous air pollution may result in the promotion of atherosclerosis, mediated, at 
least in part, by increased levels of Lp-PLA2.
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et al. 2000). Eligible study participants were 
between 35 and 80 years of age and had had 
an MI > 3 months and up to 6 years prior 
to the start of the study, corresponding to an 
MI that occurred between 1997 and 2003. 
We excluded patients who had had an MI 
or interventional procedures (percutaneous 
transluminal coronary angioplasty, coronary 
artery bypass surgery) < 3 months before 
the beginning of the study and patients who 
had chronic inflammatory diseases or who 
were taking oral anticoagulant medications, 
which can potentially affect inflammatory and 
hemostatic markers. All study participants in 
Augsburg lived within a 10-km radius of the 
central monitoring station; participants who 
had left this area for > 1 month during the 
study period were also excluded. Only cur-
rent nonsmokers or occasional smokers (< 1 
cigarette/day) were recruited. Ex-smokers were 
considered nonsmokers if they had quit smok-
ing at least 3 months before the start of the 
study. The study protocol was approved by 
the human subjects committee, Bayerische 
Landesärztekammer, and written informed 
consent was obtained from all patients at their 
first clinical visit.
Clinical measurements. At the first visit, a 
baseline questionnaire was administered regard-
ing patient characteristics such as health sta-
tus, history of coronary heart disease and other 
comorbidities, smoking history, and socio-
economic status. All medication taken during 
the course of the study was recorded, includ-
ing brand name, dose, and intake pattern. A 
blood serum sample was drawn to determine 
serum lipids including total cholesterol and 
high-  density lipoprotein (HDL) cholesterol, 
glycated hemoglobin (HbA1c), which is pro-
portional to average blood glucose concentra-
tion over the previous 4 weeks to 3 months, as 
well as N-terminal proB-type natriuretic peptide 
(NT-proBNP), an indicator of heart failure.
In general, six repeated clinical visits 
were scheduled every 4–6 weeks on the same 
weekday and at the same time of the day to 
minimize the impact of weekly and circadian 
variation. If the participant was unable to 
comply with this criterion, another day of the 
week was selected with an appointment at the 
same hour (plus or minus 1 hr). If volunteers 
suffered from acute infections such as a cold or 
influenza up to 3 days before the clinical visit, 
examinations were postponed or the respective 
blood sample was excluded from analyses.
A 7-day recall on medication intake was 
obtained. Venous ethylenediamine tetraacetic 
acid (EDTA)-plasma samples were collected 
for the determination of Lp-PLA2 mass levels 
and C-reactive protein (CRP). Samples were 
cooled and stored at 4°C until further process-
ing within a maximum of 4 hr after blood 
draw. EDTA-blood was centrifuged at 4°C in 
a precooled centrifuge for 20 min at 2,500 × g. 
Plasma aliquots were kept at –80°C until they 
were shipped on dry ice to the laboratory at 
the University of Ulm Medical Center in 
Ulm, Germany, for analyses. Plasma levels 
of Lp-PLA2 were determined with a com-
mercially available Lp-PLA2-ELISA (PLAC 
test; diaDexus, Inc., San Francisco, CA, 
USA). CRP concentrations were measured 
by a high-sensitivity latex-enhanced immu-
nonephelometry (Dade Behring GmbH, 
Marburg, Germany). The detection limits 
were 1.3 ng/mL for Lp-PLA2 and 0.16 mg/L 
for CRP. Duplicate blood samples were 
received from 11 patients and were blinded 
before determining Lp-PLA2 levels. The rela-
tive difference was 2.7% (–7.4 to 13.8) and 
the R-square (0.98) of the blinded duplicate 
blood samples showed a good agreement of 
the measurements. Further quality control 
procedures included 147 repeat measurements 
of samples from 104 participants three times 
each. The coefficient of variation was 2.07% 
(0–11.8%), and the pairwise Spearman corre-
lation coefficients were 0.99 and 0.97 between 
the three Lp-PLA2 measurements.
Air pollution and meteorological data. 
We collected air pollution data from a fixed 
monitoring site that represented urban back-
ground concentrations according to stan-
dard procedures already employed in several 
European studies of air pollution (Aalto et al. 
2005; Katsouyanni et al. 1996). Exposure 
assessment included hourly means of particu-
late matter (PM) < 10 µm (PM10), and PM 
< 2.5 µm (PM2.5) in aerodynamic diameter, 
and particle number concentrations (PNCs; 
< 100 nm), which represent ultrafine particles; 
the assessment also included gaseous air pol-
lutants [carbon monoxide (CO), sulfur diox-
ide (SO2), ozone (O3), nitric oxide (NO), and 
nitrogen dioxide (NO2)] and meteorological 
variables (air temperature, relative humidity, 
barometric pressure). Meteorological data were 
obtained through the Deutscher Wetterdienst 
(Offenbach, Germany; air monitoring network 
and meteorological services). Daily average con-
centrations of particles and gases and the 8-hr 
average of O3 were calculated if at least 75% 
of the observations were available. PNC was 
measured using a condensation particle counter 
(model 3022A; TSI Inc., St. Paul, MN, USA).
Missing data on the aggregate level were 
replaced using a formula adapted from the Air 
Pollution and Health—A European Approach 
method (Katsouyanni et al. 1996; Rückerl 
et al. 2007) [for details, see Supplemental 
Material (doi:10.1289/ehp.1002681)]. If all 
measurements were missing for 1 day, the 
averages from the day before and the day after 
were taken. If data were missing for > 24 hr, 
data were not replaced.
Statistical analyses. For each person and 
visit, we calculated individual 24-hr average 
exposures immediately preceding the clinical 
visit (lag 0) and up to 5 days before the visit 
(lag 1–lag 5).
Data were analyzed using mixed models 
with random patient effects to account for the 
repeated measures data structure. To model 
correlations between the repeated measures in 
each patient, we assumed a compound symme-
try structure for the covariance matrix, as the 
half-life of Lp-PLA2 is shorter than the inter-
vals between visits. Penalized splines (P-splines) 
in the additive mixed-models framework were 
used to allow for nonparametric exposure–
response functions (Greven et al. 2006).
We built a confounder model without 
including air pollutants. In the first step, time-
invariant factors with potential impacts on 
average Lp-PLA2 concentrations were evalu-
ated to permit the assumption of a normally 
distributed random patient intercept. These 
factors included age, sex, body mass index 
(BMI; kilograms per square meter), smoking, 
number of MIs, time since last MI, level of 
education, and working status that were clas-
sified at the time of enrollment. As further 
possible indicators for Lp-PLA2 levels, we 
considered self-reported overall health status, 
doctor’s diagnosis of diabetes, osteoarthri-
tis, hay fever, chronic renal diseases, hyper-
tension, respiratory diseases and symptoms, 
diagnosis of cardiovascular diseases (angina 
pectoris, arrhythmias, congestive heart failure, 
and stroke), the presence of a cardiac pace-
maker, blood pressure, total and HDL choles-
terol, NT-proBNP, and HbA1c levels.
In the second step, time-varying variables 
were added. To assure sufficient adjustment 
for season and meteorology, we forced long-
term time trend and air temperature into 
the model. Additionally, relative humidity 
and barometric pressure, time of the day, 
and weekday were included if this adjust-
ment proved necessary. P-splines were used 
to model continuous covariables and were 
compared with linear terms and poly  nomials 
of degree 2 and 3. All decisions on goodness-
of-fit were based on Akaike Information 
Criterion (AIC; 1973).
After completing the confounder model 
selection [see Supplemental Material, Table 1 
(doi:10.1289/ehp.1002681)], we added single 
air pollution lags, and the effects were esti-
mated linearly. The exposure–response func-
tion for the air pollutants was assessed using 
P-splines and showed no consistent deviation 
from linearity across lags, so only estimates for 
the linear function are presented. Effect esti-
mates are presented as percent change of the 
mean of Lp-PLA2 levels together with 95% 
confidence intervals (CIs) based on an increase 
in air pollution concentrations from the first to 
the third quartile [interquartile range (IQR): 
difference between the third and first quartile]. 
Data were analyzed using SAS (version 9.1; 
SAS Institute Inc., Cary, NC, USA).Ambient air pollution and lipoprotein-associated phospholipase A2
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Effect modification. Binary interaction 
variables were added to the model to estimate 
the air pollution effects of the correspond-
ing subgroups. Interaction variables were sex 
(male vs. female), season (April–September vs. 
October–March), BMI (≤ 25 kg/m² vs. > 25 
kg/m²), and CRP (≤ 3 mg/L vs. > 3 mg/L). 
An effect modification was assumed to be 
present based on p-value < 0.05.
Sensitivity analyses. To check the robust-
ness of our models, we performed several sen-
sitivity analyses. Air pollution effects were also 
estimated by adjusting for the time-varying 
confounders only. In a further sensitivity anal-
ysis, models were additionally adjusted for the 
intake of antiinflammatory and antirheumatic 
medication as well as diuretics and drugs for 
chronic obstructive pulmonary disease up to 
7 days before blood withdrawal.
We also estimated the association of each 
air pollutant with Lp-PLA2 level using an 
unconstrained distributed lag model that 
included air pollution levels for the same day 
and the 5 previous days simultaneously.
Results
Study population. Baseline characteristics of 
the study population, as well as laboratory 
results, medical history, physical activity, and 
medication, are shown in Table 1. In total, 
200 MI survivors were recruited who ful-
filled the inclusion criteria and had at least 
two valid blood samples taken. Study partici-
pants were mostly men and consisted of never 
smokers (32.5%), occasional smokers (4.5%), 
and ex-smokers (63%). On average, they were 
62 years old and had 5.7 repeat visits to the 
study center. The total number of analyzed 
blood samples was 1,142. CRP levels were in 
the range of ≤ 3 mg/L at 82% (n = 932) of 
blood samples.
Lp-PLA2 data. Lp-PLA2 was nearly nor-
mally distributed with a mean ± SD level of 
189 ± 51 ng/mL. The mean level was higher in 
men (190 ± 52 ng/mL) than in women (181 ± 
44 ng/mL), and it was higher in winter (191 ± 
54 ng/mL) than in summer (180 ± 49 ng/mL). 
For 69% of all visits, Lp-PLA2 measurements 
were higher in winter. Some participants 
showed consistently high or low Lp-PLA2-
levels during the whole study period.
Air pollutants. The distributions of the 
24-hr average concentrations of the particulate 
and gaseous pollutants as well as meteorological 
data are given in Table 2. Measurement values 
characterize the population average exposures 
typical for urban background pollution mainly 
due to traffic emissions and domestic heating 
during the winter season.
Using Spearman correlation coefficient, we 
found that PNC highly correlated with CO 
(micrograms per cubic meter; r = 0.74), NO 
(micrograms per cubic meter; r = 0.74), and 
SO2 (micrograms per cubic meter; r = 0.77) 
(Table 3). NO and CO showed the highest 
correlation (r = 0.82). PM10 and PM2.5 were 
highly correlated (r = 0.93), whereas UFP 
was only moderately correlated with PM10 
(r = 0.41) and PM2.5 (r = 0.35). A low cor-
relation was also seen for NO2 with PNC 
(r = 0.54), PM2.5 (r = 0.57), PM10 (r = 0.66), 
and CO (r = 0.67). O3 concentrations were 
negatively correlated with all pollutants and 
with relative humidity (r = –0.74) and posi-
tively correlated with temperature (r = 0.80).
Particulate and gaseous air pollutants dur-
ing the study period are shown in Supplemental 
Material, Figure 1 (doi:10.1289/ehp.1002681).
Regression results. Based on AIC, we 
selected seven time-invariant factors of 46 vari-
ables for the final confounder model: systolic 
blood pressure, serum cholesterol, time between 
MI and beginning of the study, number of MIs 
(0, 1, > 1), congestive heart failure (yes/no), 
alcohol intake (grams per day), and HbA1c 
(percent) < 6.5 (yes/no). In addition, the fol-
lowing time-varying factors were included in 
the final confounder model: trend (P-splines), 
weekday, 48-hr average of air temperature 
Table 1. Characteristics of the study population: 
200 MI survivors in Augsburg, Germany, 14 May 
2003–24 February 2004.
Characteristic
Mean ± SD or 
total n (%)
Age (years) 61.9 ± 9.0
Last MI to study (years)  2.1 ± 0.9
BMI (kg/m²) 28.8 ± 4.0
Alcohol intake per day (g) 18.5 ± 22.6
Systolic blood pressure (mmHg) 128.4 ± 19.9
Total cholesterol (mg/dL) 181.0 ± 38.8
HDL (mg/dL)  47.9 ± 11.8
HbA1c (%) 5.6 ± 0.7
CRP (mg/L) 2.2 ± 4.5
Lp-PLA2 (ng/mL) 188.6 ± 51.1
Sex (male) 164 (82)
Smoking
Ex-smokers 126 (63)
Occasional smokers 9 (4.5)
Never smokers 65 (32.5)
No. of MIs
1 175 (88)
> 1 25 (12)
BMI (kg/m²)
≤ 25 31 (16)
> 25 168 (84)
HbA1c (%)
< 6.5 181 (90)
≥ 6.5 19 (10)
Medical history 
Angina pectoris 42 (21)
Arrhythmias 48 (24)
Congestive heart failure 26 (13)
Stroke 13 (7)
Diabetes mellitus 35 (18)
Hypertension 102 (51)
Chronic bronchitis 16 (8)
Asthma 9 (5)
Emphysema 2 (1)
Hay fever 20 (10)
Chronic renal disease 10 (5)
Osteoarthritis 35 (18)
Medications
Beta blockers 183 (92)
ACE inhibitors 139 (70)
Diuretics 79 (40)
Statins 173 (87)
Fibrates 2 (1)
ACE, angiotensin converting enzyme.
Table 3. Spearman correlation coefficients of the 24‑hr average concentrations of the particulate and 
gaseous pollutants as well as meteorological data in Augsburg, Germany, 14 May 2003–24 February 2004.
Pollutant PNC PM2.5 PM10 CO NO2 NO SO2 O3 Temperature
Relative 
humidity
PNC 1
PM2.5 0.35 1
PM10 0.41 0.93 1
CO 0.74 0.58 0.61 1
NO2 0.54 0.57 0.66 0.67 1
NO 0.74 0.25 0.35 0.82 0.54 1
SO2 0.77 0.42 0.43 0.63 0.51 0.60 1
O3 (8-hr average) –0.67 –0.08 –0.10 –0.66 –0.11 –0.73 –0.45 1
Air temperature –0.61 0.12 0.12 –0.42 0.10 –0.50 –0.38 0.80 1
Relative humidity 0.23 –0.12 –0.14 0.34 –0.22 0.44 0.11 –0.74 –0.73 1
Barometric pressure 0.06 0.11 0.20 0.05 0.20 0.05 0.06 0.07 0.13 –0.29
Table 2. Description of the 24‑hr average concentrations of the particulate and gaseous pollutants as 
well as meteorological data in Augsburg, Germany, 14 May 2003–24 February 2004.
Pollutant n Sites Mean ± SD Minimum 25% Median 75% Maximum IQR
PNC (1/cm³) 198 1 11,876 ± 6,077 2,764 7,085 10,824 14,440 32,528 7,355
PM2.5 (μg/m³) 283 1 17.4 ± 6.2 6.2 12.2 16.9 21.2 38.7 8.9
PM10 (μg/m³) 286 3 33.1 ± 13.4 7.1 22.0 32.7 42.7 70.9 20.6
CO (mg/m³) 287 2 0.6 ± 0.2 0.3 0.4 0.5 0.7 1.7 0.2
NO2 (μg/m³) 287 3 40.0 ± 10.9 13.3 32.7 39.2 46.5 71.9 13.8
NO (μg/m³) 287 3 30.0 ± 24.0 7.6 17.2 23.0 32.3 176.4 15.1
SO2 (μg/m³) 287 2 3.0 ± 1.3 2.0 2.1 2.5 3.3 8.9 1.2
O3 (8-hr average) (μg/m³) 286 1 54.4 ± 36.0 3.0 20.4 56.0 82.3 137.9 61.9
Air temperature (°C) 285 1 10.2 ± 9.6 –9.4 1.9 10.3 19.6 27.6 17.7
Relative humidity (%) 285 1 69.0 ± 14.2 38.1 80.2 68.9 80.2 94.3 23.5
Barometric pressure (hPa) 285 1 1018.7 ± 6.9 991.0 1023.6 1019.8 1023.6 1032.3 8.4Brüske et al.
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(P-splines) of the same and the previous day, 
24-hr average relative humidity (P-splines) 4 
days before the blood withdrawal, and baro-
metric pressure of the same day (P-splines).
IQR increases in PM10 and PM2.5 were 
associated with a maximum percent change 
in plasma Lp-PLA2 of 3.23 (95% CI, 1.31–
5.16) and 2.65 (95% CI, 0.75–4.56) at lag 5, 
respectively, and an IQR increase in PNC was 
associated with a maximum percent change of 
2.97 (95% CI, 0.31–5.64) at lag 3 (Figure 1). 
For IQR increases in gaseous pollutants, the 
maximum percent change in Lp-PLA2 was 
observed 4 days before blood withdrawal: 2.79 
(95% CI, 1.04–4.54) for CO; 2.62 (95% 
CI, 1.08–4.16) for NO2; and 1.66 (95% CI, 
–0.13 to 3.45) for NO (Figure 2). The maxi-
mum percent change in Lp-PLA2 with an 
IQR increase in SO2 was observed at lag 5: 
2.73 (95% CI, 1.30–4.17). However, IQR 
increases in PM10, PM2.5, PNC, and NO2 
were inversely associated with Lp-PLA2 levels 
at lag 1 and lag 2. The association between 
O3 and Lp-PLA2 followed a completely dif-
ferent time pattern, with a maximum percent 
change of 2.34 (95% CI, 0.15–4.54) at lag 0.
Effect modification. Associations between 
air pollutants and Lp-PLA2 were not modified 
by sex or CRP level (p-value of interaction 
> 0.05; data not shown). Overall, associations 
of PM10, PM2.5, and NO2 with Lp-PLA2 
tended to be stronger in normal weight (BMI 
≤ 25 kg/m²) participants than in overweight 
participants [Supplemental Material, Figure 2, 
left half (doi:10.1289/ehp.1002681)]. Season 
was a strong effect modifier [Supplemental 
Material, Figure 2, right half (doi:10.1289/
ehp.1002681)]. The association of Lp-PLA2 
with PM10 and PM2.5, as well as with NO2, 
NO, and CO for lag 3-4 was seen in win-
ter, but not in summer. For p-values of inter-
action, refer to Figure 2 in Supplemental 
Material (doi:10.1289/ehp.1002681).
Sensitivity analyses. Excluding three occa-
sional smokers with 17 Lp-PLA2 measure-
ments in a sensitivity analysis had no effect on 
the results.
Adjusting for time-invariant confounders 
only or for time-invariant factors and medi-
cations only did not lead to statistically sig-
nificant changes in the air pollution Lp-PLA2 
response. The lag pattern of air pollution 
associations did not change when using dis-
tributed lag models that accounted for all lag 
periods simultaneously. However, the associa-
tions tended to be less pronounced.
Discussion
To our knowledge, this panel study of MI 
survivors is the first human study to exam-
ine the relation between air pollution and 
plasma Lp-PLA2 mass levels. Inverse asso-
ciations were observed for particulate expo-
sure and NO2 with Lp-PLA2 at lag days 1–2, 
and positive associations were estimated for 
all particulate and gaseous pollutants except 
O3 with Lp-PLA2 lagged 4 and 5 days. Our 
finding of a positive association between 
all air pollutants and Lp-PLA2 levels to lag 
4–lag 5 was observed in the single pollutant 
model as well as in the distributed lag model. 
Information on the physiological behavior of 
Lp-PLA2 levels is not sufficient to determine 
whether the early (1–2 days) inverse associa-
tions and later positive associations (4–5 days) 
observed between air pollutants and Lp-PLA2 
levels in our study population are biologically 
plausible. The immediate positive association 
with O3 suggests a different physiological 
mechanism, if associations represent causal 
effects. The independent effects of the vari-
ous pollutants could not be estimated because 
of the interrelationship among most pollut-
ants. Effects of PM air pollution on LDL lev-
els could potentially confound associations 
Figure 1. Percent changes of the mean Lp‑PLA2 per 
IQR (difference between the third and first quartile) 
in particulate air pollutants together with 95% CIs in 
Augsburg, Germany, 14 May 2003–24 February 2004.
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Figure 2. Percent changes of the mean Lp‑PLA2 per IQR (difference between the third and first quartile) in 
gaseous air pollutants together with 95% CIs in Augsburg, Germany, 14 May 2003 to 24 February 2004.
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between air pollutants and Lp-PLA2, but 
adjusting for LDL at baseline examination 
had practically no effect on associations.
As part of the AIRGENE study, repeated 
measurements of markers of inflammation 
(interleukin 6, fibrinogen, and CRP) were 
compared with concurrent levels of air pollu-
tion. An immediate association (12–17 hr) of 
interleukin 6 was seen, especially in relation 
to PNC, but no consistent associations were 
found for CRP, which was attributed to a 
widespread intake of statins in the study pop-
ulation of MI survivors (Rückerl et al. 2007). 
Based on a subset of the same study popula-
tion, we found that associations between air 
pollution and Lp-PLA2 levels occurred later 
than associations with inflammatory mark-
ers. Furthermore, individual mean levels of 
Lp-PLA2 did not correlate with individual 
mean levels of CRP (r = 0.03), fibrinogen (r = 
–0.08), or interleukin-6 (r = –0.04).
We have no explanation for why the asso-
ciation of Lp-PLA2 with PM10 and PM2.5, 
as well as with NO2, NO, and CO for 
lag 3–lag 4, was seen only in winter, but not 
in summer. It might be related to additional 
air pollutants in winter not measured in the 
study or to different human metabolism in 
winter; however, these explanations are highly 
speculative. Moreover, we cannot explain why 
the increase of Lp-PLA2 tended to be stronger 
in normal weight (BMI ≤ 25 kg /m²) com-
pared with overweighed study participants.
Based on their in vitro study, Beck-Speier 
et al. (2005) proposed that effects of particles 
on alveolar macrophage cell membranes or cell 
membrane receptors may trigger the extracel-
lular signal-regulated kinase 1,2 (ERK 1,2) 
cascade via mitogen-activated protein kinase 
kinase1, resulting in activation of cytosolic and 
secretory Lp-PLA2. Both Lp-PLA2 enzymes 
hydrolyze correspondingly substituted phospho-
lipids to produce arachidonic acid. Arachidonic 
acid, released by cytosolic PLA2, may stimulate 
secretory phospholipids A2 to amplify its libera-
tion, as proposed by Balsinde et al. (1998).
In a study of the biological variabil-
ity of Lp-PLA2 (Lerman and McConnell 
2008), the percent coefficient of variation 
of Lp-PLA2 levels within an individual was 
rather low (10%), similar to LDL cholesterol. 
This finding was confirmed recently in our 
AIRGENE study population (Khuseyinova 
et al. 2008) in which the within-subject varia-
tion in plasma Lp-PLA2 concentration was 
substantially smaller than the between-subject 
variation. For this reason, Lp-PLA2 can be 
reliably followed serially over time rendering 
it a potentially useful clinical risk marker of 
CVD. Due to this stability, one would expect 
only small changes associated with air pollu-
tion. However, because we did not evaluate 
the within-individual changes in Lp-PLA1 
concentrations, the clinical relevance of our 
observations remains uncertain.
Strengths and limitations. Our study 
offers an exploratory post-hoc analysis of the 
impact of exposure to ambient particulate 
and gaseous air pollutants on Lp-PLA2 levels. 
These data were collected in the German sub-
set of the main AIRGENE study population 
and could be analyzed only with compara-
tively low power. The observed associations 
should be regarded as preliminary.
The air pollution measurements were made 
at a single monitoring site, which may not ade-
quately reflect individual exposure, especially 
for PNC (Puustinen et al. 2007). Assuming a 
nondifferential misclassification, the true effect 
of PNC on Lp-PLA2 may have been under-
estimated. Cyrys et al. (2008) investigated 
the temporal and spatial variation of PNC at 
four urban background monitoring sites in 
Augsburg, Germany. The authors observed a 
high temporal correlation of PNC across the 
city area of Augsburg. This finding suggests 
that in epidemiological time-series studies, the 
use of one single ambient monitoring site is an 
adequate approach for characterizing exposure 
to ultrafine particles.
The study was designed to assess the 
impact of ambient air pollution on Lp-PLA2 
levels in a cohort of MI survivors assuming a 
specific susceptibility. The study population 
was prescribed evidence-based cardiovascular 
medication for the post-MI period. Medication 
is an important effect modifier in this study 
that we could not take into account adequately. 
HMG-CoA reductase inhibitors (statins), 
for example, can reduce Lp-PLA2 concentra-
tions in plasma by approximately 15–20% 
(McConnell and Hoefner 2006), but the effect 
of the medication could not be examined in 
detail because nearly all patients (87%) took 
statins. Other medications (e.g., angiotensin 
II receptor antagonists, ezetimibe, fish oil, 
and niacin) (Hill et al. 2009) may also have 
altered LpPLA2 levels. Potential intermittent 
adherence to medication may have biased the 
observed association. For subgroup analyses of 
different medication groups, the sample size, 
and thus the power of the study, was too small.
Furthermore, the study population was 
86% male with only 36 female patients and 
also was restricted with regard to age, disease, 
and medication status. Therefore, findings may 
not be generalizable to the general population.
All blood samples were collected in the 
fasting state under standardized conditions 
and mostly at the same time (98%) of the 
same weekday (95%) to minimize the impact 
of circadian and day-to-day variation. The 
Lp-PLA2 mass, but not the activity, was meas-
ured. Although previous studies have shown a 
correlation (r ~ 0.6) between activity and mass 
(Iribarren et al. 2005; Koenig et al. 2006), this 
correlation may be weakened if an individual 
has a polymorphism or mutation that influ-
ences activity of the gene product (McConnell 
and Hoefner 2006).
Conclusion
The daily time-series analysis showed a positive 
association of Lp-PLA2 mass levels with PM10, 
PM2.5, and PNC, as well as CO, NO2, NO, 
and SO2 with a delay of 4–5 days, but also 
indicated inverse associations with some pollut-
ants over shorter time lags. The accumulation 
of acute and subacute effects or the chronic 
exposure to ambient particulate and gaseous 
air pollution may result in the promotion of 
atherosclerosis, mediated at least in part by 
increased levels of Lp-PLA2 and subsequently 
increased levels of their major pro-atherogenic 
and pro-inflammatory downstream products. 
However, these associations have not been eval-
uated previously, and results must be replicated 
before chance associations can be ruled out.
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